{
  "doc_id": "8pn_pn_for_specialized_patient__5f5a3e",
  "original_filename": "8PN PN for Specialized Patient.pdf",
  "md_path": "data/parsed/8PN PN for Specialized Patient/8PN PN for Specialized Patient.md",
  "rmd_path": "data/parsed/8PN PN for Specialized Patient/8PN PN for Specialized Patient.rmd",
  "blocks": [
    {
      "type": "heading",
      "level": 1,
      "section": "Parenteral Nutrition (PN) for the Specialized Patient",
      "line": 0
    },
    {
      "type": "text",
      "section": "Parenteral Nutrition (PN) for the Specialized Patient",
      "line": 2,
      "preview": "--- page 1 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Outline",
      "line": 4
    },
    {
      "type": "text",
      "section": "Outline",
      "line": 6,
      "preview": "- Case"
    },
    {
      "type": "text",
      "section": "Outline",
      "line": 7,
      "preview": "- Parenteral nutrition considerations in"
    },
    {
      "type": "text",
      "section": "Outline",
      "line": 8,
      "preview": "- Critical illness"
    },
    {
      "type": "text",
      "section": "Outline",
      "line": 9,
      "preview": "- Extracorporeal membrane oxygenation (ECMO)"
    },
    {
      "type": "text",
      "section": "Outline",
      "line": 10,
      "preview": "- Chylothorax"
    },
    {
      "type": "text",
      "section": "Outline",
      "line": 11,
      "preview": "- GI surgery, high ostomies"
    },
    {
      "type": "text",
      "section": "Outline",
      "line": 12,
      "preview": "- Liver disease"
    },
    {
      "type": "text",
      "section": "Outline",
      "line": 13,
      "preview": "- Renal disease"
    },
    {
      "type": "text",
      "section": "Outline",
      "line": 14,
      "preview": "- Inborn errors of metabolism"
    },
    {
      "type": "text",
      "section": "Outline",
      "line": 15,
      "preview": "- Short bowel syndrome/Intestinal Failure"
    },
    {
      "type": "text",
      "section": "Outline",
      "line": 16,
      "preview": "- Case review"
    },
    {
      "type": "text",
      "section": "Outline",
      "line": 18,
      "preview": "--- page 2 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Case",
      "line": 20
    },
    {
      "type": "text",
      "section": "Case",
      "line": 22,
      "preview": "Lucy is a 5-month-old with biliary atresia and progressive end stage liver disease who is listed for"
    },
    {
      "type": "text",
      "section": "Case",
      "line": 24,
      "preview": "1) What information would you like to assess her nutrition?"
    },
    {
      "type": "text",
      "section": "Case",
      "line": 25,
      "preview": "2) Would you recommend parenteral nutrition and when?"
    },
    {
      "type": "text",
      "section": "Case",
      "line": 26,
      "preview": "3) What factors would influence the energy requirements of this patient?"
    },
    {
      "type": "text",
      "section": "Case",
      "line": 28,
      "preview": "--- page 3 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "**Pathophysiology of Injury in Pediatric Intensive Care (PICU)**",
      "line": 30
    },
    {
      "type": "text",
      "section": "**Pathophysiology of Injury in Pediatric Intensive Care (PICU)**",
      "line": 32,
      "preview": "Traditionally considered pre-resuscitative ebb phase and 'often' hypometabolic"
    },
    {
      "type": "text",
      "section": "**Pathophysiology of Injury in Pediatric Intensive Care (PICU)**",
      "line": 34,
      "preview": "Traditionally considered flow phase and 'often' hypermetabolism"
    },
    {
      "type": "image",
      "section": "**Pathophysiology of Injury in Pediatric Intensive Care (PICU)**",
      "line": 36,
      "content": "![img-0.jpeg](images/a539799643230942.png)"
    },
    {
      "type": "image",
      "section": "**Pathophysiology of Injury in Pediatric Intensive Care (PICU)**",
      "line": 38,
      "content": "![img-1.jpeg](images/013681fe3fbd5a0a.png)"
    },
    {
      "type": "image",
      "section": "**Pathophysiology of Injury in Pediatric Intensive Care (PICU)**",
      "line": 40,
      "content": "![img-2.jpeg](images/8324f0d123479d4e.png)"
    },
    {
      "type": "text",
      "section": "**Pathophysiology of Injury in Pediatric Intensive Care (PICU)**",
      "line": 42,
      "preview": "--- page 4 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "**Impact on Intermediary Metabolism**",
      "line": 44
    },
    {
      "type": "heading",
      "level": 2,
      "section": "**CNS Hormones & Catecholamines**",
      "line": 46
    },
    {
      "type": "text",
      "section": "**CNS Hormones & Catecholamines**",
      "line": 48,
      "preview": "- \u2191 gluconeogenesis"
    },
    {
      "type": "text",
      "section": "**CNS Hormones & Catecholamines**",
      "line": 49,
      "preview": "- \u2191 glycolysis"
    },
    {
      "type": "text",
      "section": "**CNS Hormones & Catecholamines**",
      "line": 50,
      "preview": "- \u2191 insulin resistance"
    },
    {
      "type": "text",
      "section": "**CNS Hormones & Catecholamines**",
      "line": 51,
      "preview": "- \u2191 lipolysis & FFA release"
    },
    {
      "type": "text",
      "section": "**CNS Hormones & Catecholamines**",
      "line": 52,
      "preview": "- \u2191 proteolysis & hepatic synthesis acute phase proteins"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "**Cytokines**",
      "line": 54
    },
    {
      "type": "text",
      "section": "**Cytokines**",
      "line": 56,
      "preview": "- \u2191 proteolysis exceeds synthesis with \u2191 urinary nitrogen"
    },
    {
      "type": "text",
      "section": "**Cytokines**",
      "line": 57,
      "preview": "- \u2191 lipolysis"
    },
    {
      "type": "text",
      "section": "**Cytokines**",
      "line": 58,
      "preview": "- \u2191 insulin resistance"
    },
    {
      "type": "text",
      "section": "**Cytokines**",
      "line": 59,
      "preview": "- \u2191 demand for and use of oxygen in tissues"
    },
    {
      "type": "image",
      "section": "**Cytokines**",
      "line": 61,
      "content": "![img-3.jpeg](images/0f19ada61a1b6016.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "**Together results in catabolism with resistance to anabolism causing:**",
      "line": 63
    },
    {
      "type": "text",
      "section": "**Together results in catabolism with resistance to anabolism causing:**",
      "line": 65,
      "preview": "- Skeletal muscle wasting"
    },
    {
      "type": "text",
      "section": "**Together results in catabolism with resistance to anabolism causing:**",
      "line": 66,
      "preview": "- Hyperglycemia"
    },
    {
      "type": "text",
      "section": "**Together results in catabolism with resistance to anabolism causing:**",
      "line": 67,
      "preview": "- High free fatty acids"
    },
    {
      "type": "text",
      "section": "**Together results in catabolism with resistance to anabolism causing:**",
      "line": 68,
      "preview": "- Hypertriglyceridemia"
    },
    {
      "type": "text",
      "section": "**Together results in catabolism with resistance to anabolism causing:**",
      "line": 69,
      "preview": "- High lactate levels"
    },
    {
      "type": "image",
      "section": "**Together results in catabolism with resistance to anabolism causing:**",
      "line": 71,
      "content": "![img-4.jpeg](images/b655ac13d660bc34.png)"
    },
    {
      "type": "image",
      "section": "**Together results in catabolism with resistance to anabolism causing:**",
      "line": 73,
      "content": "![img-5.jpeg](images/043b2541a4580ede.png)"
    },
    {
      "type": "text",
      "section": "**Together results in catabolism with resistance to anabolism causing:**",
      "line": 75,
      "preview": "--- page 5 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "**Concepts of Inflammation and Immunosuppression in Critical Illness**",
      "line": 77
    },
    {
      "type": "text",
      "section": "**Concepts of Inflammation and Immunosuppression in Critical Illness**",
      "line": 79,
      "preview": "- These patients are at high risk for severe malnutrition: another risk factor for secondary infecti"
    },
    {
      "type": "text",
      "section": "**Concepts of Inflammation and Immunosuppression in Critical Illness**",
      "line": 81,
      "preview": "- Going forward it will be important to understand if nutrition support in PICU might modify **Syste"
    },
    {
      "type": "image",
      "section": "**Concepts of Inflammation and Immunosuppression in Critical Illness**",
      "line": 83,
      "content": "![img-6.jpeg](images/1800be7bdf53c13f.png)"
    },
    {
      "type": "image",
      "section": "**Concepts of Inflammation and Immunosuppression in Critical Illness**",
      "line": 85,
      "content": "![img-7.jpeg](images/2826f026e7c8a01c.png)"
    },
    {
      "type": "text",
      "section": "**Concepts of Inflammation and Immunosuppression in Critical Illness**",
      "line": 87,
      "preview": "--- page 6 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Malnutrition in Critical Illness",
      "line": 89
    },
    {
      "type": "text",
      "section": "Malnutrition in Critical Illness",
      "line": 91,
      "preview": "- Undernutrition is common in patients admitted to PICU (20-45\\%)"
    },
    {
      "type": "text",
      "section": "Malnutrition in Critical Illness",
      "line": 92,
      "preview": "- Obesity increasingly common"
    },
    {
      "type": "text",
      "section": "Malnutrition in Critical Illness",
      "line": 93,
      "preview": "- Catabolism with rapid loss of protein stores expected in all"
    },
    {
      "type": "text",
      "section": "Malnutrition in Critical Illness",
      "line": 94,
      "preview": "- Greatest risk for undernourished children, neonates and infants"
    },
    {
      "type": "text",
      "section": "Malnutrition in Critical Illness",
      "line": 95,
      "preview": "- Muscle loss and loss of muscle function results in sarcopenia, which increases risks:"
    },
    {
      "type": "text",
      "section": "Malnutrition in Critical Illness",
      "line": 96,
      "preview": "- Prolonged ventilation"
    },
    {
      "type": "text",
      "section": "Malnutrition in Critical Illness",
      "line": 97,
      "preview": "- Acquired pneumonia"
    },
    {
      "type": "text",
      "section": "Malnutrition in Critical Illness",
      "line": 98,
      "preview": "- Prolonged length of stay"
    },
    {
      "type": "text",
      "section": "Malnutrition in Critical Illness",
      "line": 99,
      "preview": "- Mortality"
    },
    {
      "type": "text",
      "section": "Malnutrition in Critical Illness",
      "line": 100,
      "preview": "- Prolonged rehabilitation for survivors"
    },
    {
      "type": "text",
      "section": "Malnutrition in Critical Illness",
      "line": 102,
      "preview": "--- page 7 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "**APSPEN Guidelines**",
      "line": 104
    },
    {
      "type": "table",
      "section": "**APSPEN Guidelines**",
      "line": 106,
      "preview": "|  Clinical Guidelines | ASPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 107,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 108,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 109,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 110,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 111,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 112,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 113,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 114,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 115,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 116,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 117,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 118,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 119,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 120,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 121,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 122,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 123,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 124,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 125,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 126,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 127,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 128,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 129,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 130,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 131,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 132,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 133,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 134,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 135,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 136,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 137,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 138,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 139,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 140,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 141,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 142,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 143,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 144,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 145,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 146,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 147,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 148,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 149,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 150,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 151,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 152,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 153,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 154,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 155,
      "preview": "AAPEN"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 156,
      "preview": "AAP"
    },
    {
      "type": "text",
      "section": "**APSPEN Guidelines**",
      "line": 158,
      "preview": "--- page 8 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "The Role of Nutrition Support",
      "line": 160
    },
    {
      "type": "text",
      "section": "The Role of Nutrition Support",
      "line": 162,
      "preview": "- Malnutrition is associated with worse outcomes in PICU"
    },
    {
      "type": "text",
      "section": "The Role of Nutrition Support",
      "line": 163,
      "preview": "- Achieving 60% of energy or protein delivery targets within 7 days after PICU admission associated "
    },
    {
      "type": "image",
      "section": "The Role of Nutrition Support",
      "line": 165,
      "content": "![img-8.jpeg](images/ac8a03468b7f0976.png)"
    },
    {
      "type": "text",
      "section": "The Role of Nutrition Support",
      "line": 167,
      "preview": "Regardless of nutrition support strategy"
    },
    {
      "type": "text",
      "section": "The Role of Nutrition Support",
      "line": 169,
      "preview": "--- page 9 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 171
    },
    {
      "type": "text",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 173,
      "preview": "- A functional gut should always be used for enteral nutrition (EN), including in critical illness w"
    },
    {
      "type": "text",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 174,
      "preview": "- EN Contraindicated if: anatomical disruption, obstruction or ischemia"
    },
    {
      "type": "text",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 175,
      "preview": "- PN Indicated when cannot use gut"
    },
    {
      "type": "table",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 177,
      "preview": "|  Benefits | Limitations  |"
    },
    {
      "type": "table",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 178,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 179,
      "preview": "|  Reduce gut atrophy | Increase gut oxygen needs; can be"
    },
    {
      "type": "table",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 180,
      "preview": "contraindicated in severe shock  |"
    },
    {
      "type": "table",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 181,
      "preview": "|  Improve gut motility | Risk of Aspiration  |"
    },
    {
      "type": "table",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 182,
      "preview": "|  Reduced infections (enhanced gut"
    },
    {
      "type": "text",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 183,
      "preview": "immune function and avoidance of"
    },
    {
      "type": "table",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 184,
      "preview": "translocation) | Frequent interruptions for fasting"
    },
    {
      "type": "text",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 185,
      "preview": "for diagnostic and other"
    },
    {
      "type": "text",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 186,
      "preview": "procedures limit efficacy,"
    },
    {
      "type": "text",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 187,
      "preview": "especially in malnourished"
    },
    {
      "type": "table",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 188,
      "preview": "patients  |"
    },
    {
      "type": "table",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 189,
      "preview": "|  Less likely to overfeed | Risk of underfeeding  |"
    },
    {
      "type": "table",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 190,
      "preview": "|  Cost effective |   |"
    },
    {
      "type": "text",
      "section": "Route of Nutrition Support in Critical Illness",
      "line": 192,
      "preview": "--- page 10 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "What is the Role \\& Timing of Supplemental PN?",
      "line": 194
    },
    {
      "type": "text",
      "section": "What is the Role \\& Timing of Supplemental PN?",
      "line": 196,
      "preview": "- Based on lack of evidence timing to start supplemental PN when EN intake is insufficient remains c"
    },
    {
      "type": "text",
      "section": "What is the Role \\& Timing of Supplemental PN?",
      "line": 197,
      "preview": "- 2017 Guideline [low quality evidence, weak recommendations]:"
    },
    {
      "type": "text",
      "section": "What is the Role \\& Timing of Supplemental PN?",
      "line": 198,
      "preview": "- Start PN If cannot start EN"
    },
    {
      "type": "text",
      "section": "What is the Role \\& Timing of Supplemental PN?",
      "line": 199,
      "preview": "- Based on a single RCT, do not start PN within 24 h of admission"
    },
    {
      "type": "text",
      "section": "What is the Role \\& Timing of Supplemental PN?",
      "line": 200,
      "preview": "- Based on a single RCT, delay supplemental PN until 1 week after PICU admission for patients with n"
    },
    {
      "type": "text",
      "section": "What is the Role \\& Timing of Supplemental PN?",
      "line": 201,
      "preview": "- Use caution applying that approach to neonates or children with malnutrition at admission to PICU,"
    },
    {
      "type": "text",
      "section": "What is the Role \\& Timing of Supplemental PN?",
      "line": 203,
      "preview": "--- page 11 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 205
    },
    {
      "type": "text",
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 207,
      "preview": "- Multicenter, prospective, randomized, controlled, parallel-group superiority trial (unblinded)"
    },
    {
      "type": "text",
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 208,
      "preview": "- 723 patients receiving early PN within 24 hours after ICU admission"
    },
    {
      "type": "text",
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 209,
      "preview": "- 717 patients received late PN on day 8 if still $<80 \\%$ of target EN requirements"
    },
    {
      "type": "text",
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 210,
      "preview": "- All patients started early enteral nutrition (EEN) within 24h"
    },
    {
      "type": "text",
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 211,
      "preview": "- EN advanced for all per protocol"
    },
    {
      "type": "text",
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 212,
      "preview": "- Newborn - 17 years (45\\% infants)"
    },
    {
      "type": "text",
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 213,
      "preview": "- Preterm neonates were excluded"
    },
    {
      "type": "text",
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 215,
      "preview": "--- page 12 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 217
    },
    {
      "type": "text",
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 219,
      "preview": "- No differences in mortality"
    },
    {
      "type": "text",
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 220,
      "preview": "- Late PN group had less infections (10.7\\% vs 18.5\\%; p<0.001)"
    },
    {
      "type": "text",
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 221,
      "preview": "- Late PN group had shorter ICU stay (9.2 vs 6.5d; p<0.001)"
    },
    {
      "type": "text",
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 222,
      "preview": "- Late PN group had shorter duration ventilation ( $p=0.001$ )"
    },
    {
      "type": "text",
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 223,
      "preview": "- Late PN group had less renal replacement therapy ( $p=0.04$ )"
    },
    {
      "type": "text",
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 224,
      "preview": "- Late PN group had shorter hospital stay (21.3 vs 17.2d; $p=0.001$ )"
    },
    {
      "type": "text",
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 225,
      "preview": "- Late PN group had more hypoglycemia ( $9.1 \\%$ vs $4.8 \\% ; p=0.001$ )"
    },
    {
      "type": "text",
      "section": "The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Trial",
      "line": 227,
      "preview": "--- page 13 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Limitations of the PEPaNIC Trial",
      "line": 229
    },
    {
      "type": "text",
      "section": "Limitations of the PEPaNIC Trial",
      "line": 231,
      "preview": "- 77\\% of late PN group discharged prior to starting PN"
    },
    {
      "type": "text",
      "section": "Limitations of the PEPaNIC Trial",
      "line": 232,
      "preview": "- 55\\% of early PN group discharged by day 4"
    },
    {
      "type": "text",
      "section": "Limitations of the PEPaNIC Trial",
      "line": 233,
      "preview": "- likely would tolerate EN and not need PN"
    },
    {
      "type": "text",
      "section": "Limitations of the PEPaNIC Trial",
      "line": 234,
      "preview": "- Protein and energy provision was estimated so that both groups may have had either over and under "
    },
    {
      "type": "text",
      "section": "Limitations of the PEPaNIC Trial",
      "line": 235,
      "preview": "- Parenteral nutrient delivery was not standardized"
    },
    {
      "type": "text",
      "section": "Limitations of the PEPaNIC Trial",
      "line": 236,
      "preview": "- Risk of overfeeding particularly high in early PN group"
    },
    {
      "type": "text",
      "section": "Limitations of the PEPaNIC Trial",
      "line": 237,
      "preview": "- Overfeeding known risk factor for infections with PN"
    },
    {
      "type": "text",
      "section": "Limitations of the PEPaNIC Trial",
      "line": 238,
      "preview": "- Majority sample did not screen at nutritional risk and were normal weight limiting generalizabilit"
    },
    {
      "type": "text",
      "section": "Limitations of the PEPaNIC Trial",
      "line": 240,
      "preview": "--- page 14 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Risks of Underfeeding in Critical Illness",
      "line": 242
    },
    {
      "type": "text",
      "section": "Risks of Underfeeding in Critical Illness",
      "line": 244,
      "preview": "- Hypoglycemia"
    },
    {
      "type": "text",
      "section": "Risks of Underfeeding in Critical Illness",
      "line": 245,
      "preview": "- Progressive sarcopenia in PICU"
    },
    {
      "type": "text",
      "section": "Risks of Underfeeding in Critical Illness",
      "line": 246,
      "preview": "- Prolonged ventilation due to sarcopenia"
    },
    {
      "type": "text",
      "section": "Risks of Underfeeding in Critical Illness",
      "line": 247,
      "preview": "- Increased infection risk"
    },
    {
      "type": "text",
      "section": "Risks of Underfeeding in Critical Illness",
      "line": 248,
      "preview": "- Poor wound healing"
    },
    {
      "type": "text",
      "section": "Risks of Underfeeding in Critical Illness",
      "line": 249,
      "preview": "- Prolonged sarcopenia post PICU stay requiring rehabilitation"
    },
    {
      "type": "text",
      "section": "Risks of Underfeeding in Critical Illness",
      "line": 250,
      "preview": "- Potential to adversely impact neurocognitive and psychomotor development"
    },
    {
      "type": "text",
      "section": "Risks of Underfeeding in Critical Illness",
      "line": 252,
      "preview": "--- page 15 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Risks of Overfeeding in Critical Illness",
      "line": 254
    },
    {
      "type": "text",
      "section": "Risks of Overfeeding in Critical Illness",
      "line": 256,
      "preview": "- Hyperglycemia, which increases risk of sepsis and poor wound healing"
    },
    {
      "type": "text",
      "section": "Risks of Overfeeding in Critical Illness",
      "line": 257,
      "preview": "- Hypertriglyceridemia"
    },
    {
      "type": "text",
      "section": "Risks of Overfeeding in Critical Illness",
      "line": 258,
      "preview": "- Hepatic steatosis"
    },
    {
      "type": "text",
      "section": "Risks of Overfeeding in Critical Illness",
      "line": 259,
      "preview": "- Cholestasis"
    },
    {
      "type": "text",
      "section": "Risks of Overfeeding in Critical Illness",
      "line": 260,
      "preview": "- Uremia"
    },
    {
      "type": "text",
      "section": "Risks of Overfeeding in Critical Illness",
      "line": 261,
      "preview": "- Ventilator dependency with hypercapnia from glucose overfeeding"
    },
    {
      "type": "text",
      "section": "Risks of Overfeeding in Critical Illness",
      "line": 263,
      "preview": "--- page 16 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "**Until the Best Approach is Known Consider an Individualized Approach?**",
      "line": 265
    },
    {
      "type": "text",
      "section": "**Until the Best Approach is Known Consider an Individualized Approach?**",
      "line": 267,
      "preview": "- Delay PN 7 days if risk of overfeeding"
    },
    {
      "type": "text",
      "section": "**Until the Best Approach is Known Consider an Individualized Approach?**",
      "line": 268,
      "preview": "- Only use if not meeting 60% of EN goals and advancing"
    },
    {
      "type": "text",
      "section": "**Until the Best Approach is Known Consider an Individualized Approach?**",
      "line": 269,
      "preview": "- Consider supplemental PN 3-5 days if risk of underfeeding"
    },
    {
      "type": "image",
      "section": "**Until the Best Approach is Known Consider an Individualized Approach?**",
      "line": 271,
      "content": "![img-9.jpeg](images/fed14a0d18f5548f.png)"
    },
    {
      "type": "image",
      "section": "**Until the Best Approach is Known Consider an Individualized Approach?**",
      "line": 273,
      "content": "![img-10.jpeg](images/88f8236e627e47f6.png)"
    },
    {
      "type": "text",
      "section": "**Until the Best Approach is Known Consider an Individualized Approach?**",
      "line": 275,
      "preview": "--- page 17 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Parenteral Energy Requirements",
      "line": 277
    },
    {
      "type": "text",
      "section": "Parenteral Energy Requirements",
      "line": 279,
      "preview": "- Energy requirements are highly variable in PICU"
    },
    {
      "type": "text",
      "section": "Parenteral Energy Requirements",
      "line": 280,
      "preview": "- Often lower than predicted, e.g., sedation, ventilation, paralysis, PN (NPO)"
    },
    {
      "type": "text",
      "section": "Parenteral Energy Requirements",
      "line": 281,
      "preview": "- Can be higher, e.g., CNS injury with dysautonomia, burns"
    },
    {
      "type": "text",
      "section": "Parenteral Energy Requirements",
      "line": 282,
      "preview": "- Predictive equations for energy have limited accuracy"
    },
    {
      "type": "text",
      "section": "Parenteral Energy Requirements",
      "line": 283,
      "preview": "- But due to lack of access to calorimetry are widely used"
    },
    {
      "type": "text",
      "section": "Parenteral Energy Requirements",
      "line": 285,
      "preview": "--- page 18 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Parenteral Energy Requirements - Cont'd",
      "line": 287
    },
    {
      "type": "text",
      "section": "Parenteral Energy Requirements - Cont'd",
      "line": 289,
      "preview": "- 2017 Guideline [low quality evidence, weak recommendations]"
    },
    {
      "type": "text",
      "section": "Parenteral Energy Requirements - Cont'd",
      "line": 290,
      "preview": "- Use calorimetry to guide energy goals"
    },
    {
      "type": "text",
      "section": "Parenteral Energy Requirements - Cont'd",
      "line": 291,
      "preview": "- In the absence of calorimetry use Schofield/FAO/WHO/UNU equations"
    },
    {
      "type": "text",
      "section": "Parenteral Energy Requirements - Cont'd",
      "line": 292,
      "preview": "- NOT Harris Benedict or RDA"
    },
    {
      "type": "text",
      "section": "Parenteral Energy Requirements - Cont'd",
      "line": 293,
      "preview": "- DO NOT add stress factors"
    },
    {
      "type": "text",
      "section": "Parenteral Energy Requirements - Cont'd",
      "line": 294,
      "preview": "- Target at least $2 / 3$ of goal energy be end of first week in PICU"
    },
    {
      "type": "text",
      "section": "Parenteral Energy Requirements - Cont'd",
      "line": 295,
      "preview": "- Individualize approach according to baseline nutrition and risk for over or underfeeding"
    },
    {
      "type": "text",
      "section": "Parenteral Energy Requirements - Cont'd",
      "line": 297,
      "preview": "--- page 19 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Priority Patients for Measuring Resting Energy Expenditure (REE) in PICU",
      "line": 299
    },
    {
      "type": "text",
      "section": "Priority Patients for Measuring Resting Energy Expenditure (REE) in PICU",
      "line": 301,
      "preview": "1. Malnutrition (BMI<5th percentile) or overweight (BMI $>85^{\\text {th }}$ )"
    },
    {
      "type": "text",
      "section": "Priority Patients for Measuring Resting Energy Expenditure (REE) in PICU",
      "line": 302,
      "preview": "2. $>10 \\%$ weight gain or loss during PICU stay"
    },
    {
      "type": "text",
      "section": "Priority Patients for Measuring Resting Energy Expenditure (REE) in PICU",
      "line": 303,
      "preview": "3. Failure to consistently meet prescribed caloric goals"
    },
    {
      "type": "text",
      "section": "Priority Patients for Measuring Resting Energy Expenditure (REE) in PICU",
      "line": 304,
      "preview": "4. Failure to wean or escalation in respiratory support"
    },
    {
      "type": "text",
      "section": "Priority Patients for Measuring Resting Energy Expenditure (REE) in PICU",
      "line": 305,
      "preview": "5. Need for muscle relaxants $>7$ days"
    },
    {
      "type": "text",
      "section": "Priority Patients for Measuring Resting Energy Expenditure (REE) in PICU",
      "line": 306,
      "preview": "6. Need for ventilation $>7$ days"
    },
    {
      "type": "text",
      "section": "Priority Patients for Measuring Resting Energy Expenditure (REE) in PICU",
      "line": 307,
      "preview": "7. CNS trauma (injury, hypoxia, ischemia) with dysautonomia"
    },
    {
      "type": "text",
      "section": "Priority Patients for Measuring Resting Energy Expenditure (REE) in PICU",
      "line": 308,
      "preview": "8. Oncologic diagnosis"
    },
    {
      "type": "text",
      "section": "Priority Patients for Measuring Resting Energy Expenditure (REE) in PICU",
      "line": 309,
      "preview": "9. PICU stay $>14$ days"
    },
    {
      "type": "text",
      "section": "Priority Patients for Measuring Resting Energy Expenditure (REE) in PICU",
      "line": 310,
      "preview": "10. Suspect Hypometabolism (e.g., hypothermia/cooling, drug induced coma) or Hypermetabolism (e.g., "
    },
    {
      "type": "text",
      "section": "Priority Patients for Measuring Resting Energy Expenditure (REE) in PICU",
      "line": 312,
      "preview": "--- page 20 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Parenteral Protein Requirements",
      "line": 314
    },
    {
      "type": "text",
      "section": "Parenteral Protein Requirements",
      "line": 316,
      "preview": "- Both protein breakdown and synthesis are increased in critical illness"
    },
    {
      "type": "text",
      "section": "Parenteral Protein Requirements",
      "line": 317,
      "preview": "- Negative nitrogen balance results"
    },
    {
      "type": "text",
      "section": "Parenteral Protein Requirements",
      "line": 318,
      "preview": "- Protein supply is critical and often underestimated"
    },
    {
      "type": "text",
      "section": "Parenteral Protein Requirements",
      "line": 319,
      "preview": "- Bedside tools to evaluate nitrogen balance limited (especially in renal impairment)"
    },
    {
      "type": "text",
      "section": "Parenteral Protein Requirements",
      "line": 320,
      "preview": "- Increased requirement in burns, gastrointestinal losses, open wounds, continuous renal replacement"
    },
    {
      "type": "text",
      "section": "Parenteral Protein Requirements",
      "line": 321,
      "preview": "- 2017 Guideline [moderate quality evidence, strong recommendations]"
    },
    {
      "type": "text",
      "section": "Parenteral Protein Requirements",
      "line": 322,
      "preview": "- Provide a minimum of $1.5 \\mathrm{~g} / \\mathrm{kg} /$ day protein (and more in infants)"
    },
    {
      "type": "text",
      "section": "Parenteral Protein Requirements",
      "line": 323,
      "preview": "- Do not use RDA (recommended daily allowance) as will be insufficient"
    },
    {
      "type": "text",
      "section": "Parenteral Protein Requirements",
      "line": 325,
      "preview": "--- page 21 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "**Both Important to Achieve Positive Nitrogen Balance**",
      "line": 327
    },
    {
      "type": "image",
      "section": "**Both Important to Achieve Positive Nitrogen Balance**",
      "line": 329,
      "content": "![img-11.jpeg](images/d062e973d383167c.png)"
    },
    {
      "type": "text",
      "section": "**Both Important to Achieve Positive Nitrogen Balance**",
      "line": 331,
      "preview": "- Systematic review 9 studies 1981-2011 (n=347) children with heterogenous diagnoses admitted to PIC"
    },
    {
      "type": "text",
      "section": "**Both Important to Achieve Positive Nitrogen Balance**",
      "line": 332,
      "preview": "- Positive balance with protein intake > 1.5g/kg/d or energy intake > 57Kcal/kg/day"
    },
    {
      "type": "image",
      "section": "**Both Important to Achieve Positive Nitrogen Balance**",
      "line": 334,
      "content": "![img-12.jpeg](images/334459a1fcc1637a.png)"
    },
    {
      "type": "image",
      "section": "**Both Important to Achieve Positive Nitrogen Balance**",
      "line": 336,
      "content": "![img-13.jpeg](images/42365217c90fcc33.png)"
    },
    {
      "type": "text",
      "section": "**Both Important to Achieve Positive Nitrogen Balance**",
      "line": 338,
      "preview": "--- page 22 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Extracorporeal Membrane Oxygenation (ECMO)",
      "line": 340
    },
    {
      "type": "text",
      "section": "Extracorporeal Membrane Oxygenation (ECMO)",
      "line": 342,
      "preview": "- Indicated for severe cardiac and/or respiratory failure"
    },
    {
      "type": "text",
      "section": "Extracorporeal Membrane Oxygenation (ECMO)",
      "line": 343,
      "preview": "- Evidence base limited to expert opinion and case series"
    },
    {
      "type": "text",
      "section": "Extracorporeal Membrane Oxygenation (ECMO)",
      "line": 344,
      "preview": "- EN safe for 75-90\\% of patients on ECMO"
    },
    {
      "type": "text",
      "section": "Extracorporeal Membrane Oxygenation (ECMO)",
      "line": 345,
      "preview": "- Feeding intolerance is common, up to $50 \\%$"
    },
    {
      "type": "text",
      "section": "Extracorporeal Membrane Oxygenation (ECMO)",
      "line": 346,
      "preview": "- Acknowledged risk for gut hypoperfusion, although severe GI complications reportedly rare"
    },
    {
      "type": "text",
      "section": "Extracorporeal Membrane Oxygenation (ECMO)",
      "line": 347,
      "preview": "- PN (total parenteral nutrition with nil enteral) may be preferred in unstable patients with escala"
    },
    {
      "type": "text",
      "section": "Extracorporeal Membrane Oxygenation (ECMO)",
      "line": 349,
      "preview": "--- page 23 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "ECMO \u2013 Cont'd",
      "line": 351
    },
    {
      "type": "text",
      "section": "ECMO \u2013 Cont'd",
      "line": 353,
      "preview": "- REE not readily measured or predicted by current equations"
    },
    {
      "type": "text",
      "section": "ECMO \u2013 Cont'd",
      "line": 354,
      "preview": "- EN has *risk of underfeeding* given feeding intolerance"
    },
    {
      "type": "text",
      "section": "ECMO \u2013 Cont'd",
      "line": 355,
      "preview": "- Supplemental PN can increase protein and energy delivery, but *risk of overfeeding*"
    },
    {
      "type": "text",
      "section": "ECMO \u2013 Cont'd",
      "line": 356,
      "preview": "- Start supplemental PN 5-7 days well nourished or 3-5 days in malnourished children"
    },
    {
      "type": "image",
      "section": "ECMO \u2013 Cont'd",
      "line": 358,
      "content": "![img-14.jpeg](images/3bd31495da6374cd.png)"
    },
    {
      "type": "image",
      "section": "ECMO \u2013 Cont'd",
      "line": 360,
      "content": "![img-15.jpeg](images/5212fcce0f1d5c83.png)"
    },
    {
      "type": "image",
      "section": "ECMO \u2013 Cont'd",
      "line": 362,
      "content": "![img-16.jpeg](images/7dd0884bfa68c9e1.png)"
    },
    {
      "type": "image",
      "section": "ECMO \u2013 Cont'd",
      "line": 364,
      "content": "![img-17.jpeg](images/d41f0f0ac4faf52a.png)"
    },
    {
      "type": "text",
      "section": "ECMO \u2013 Cont'd",
      "line": 366,
      "preview": "--- page 24 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Chylothorax",
      "line": 368
    },
    {
      "type": "text",
      "section": "Chylothorax",
      "line": 370,
      "preview": "- Common complication in PICU after cardiac surgery, 5\\%"
    },
    {
      "type": "text",
      "section": "Chylothorax",
      "line": 371,
      "preview": "- Majority can be managed medically: median chain triglyceride (MCT) enriched EN first line treatmen"
    },
    {
      "type": "text",
      "section": "Chylothorax",
      "line": 372,
      "preview": "- No RCTs comparing MCT-rich EN to PN and nil per os"
    },
    {
      "type": "text",
      "section": "Chylothorax",
      "line": 373,
      "preview": "- PN (with lipids) may be indicated if refractory to EN or high-volume losses $>10 \\mathrm{ml} / \\ma"
    },
    {
      "type": "text",
      "section": "Chylothorax",
      "line": 374,
      "preview": "- More than $80 \\%$ effective, without further medication or surgery"
    },
    {
      "type": "text",
      "section": "Chylothorax",
      "line": 375,
      "preview": "- Risk of nutritional losses and immunosuppression"
    },
    {
      "type": "text",
      "section": "Chylothorax",
      "line": 376,
      "preview": "- Chylous fluid has 20-60g/L protein, electrolytes, trace minerals, immune cells and immunoglobulins"
    },
    {
      "type": "text",
      "section": "Chylothorax",
      "line": 377,
      "preview": "- Monitor for EFAD if extended use of MCT-rich EN, although rare"
    },
    {
      "type": "text",
      "section": "Chylothorax",
      "line": 379,
      "preview": "--- page 25 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 381
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 383,
      "preview": "- Massive intestinal resection induces major functional and metabolic changes in the GI tract"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 384,
      "preview": "- Loss of inhibitory reflexes of the enteric nervous system including cologastric and ileogastric re"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 385,
      "preview": "- Decrease in enterohormones leading to accelerated gastric emptying and increased gastric secretion"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 386,
      "preview": "- Bile acid loss"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 387,
      "preview": "- Major net loss of fluids and electrolyte via end-jejunostomy"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 388,
      "preview": "- Losses worsened by oral intake"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 389,
      "preview": "- PN mixture must meet higher hydration needs and compensate nutrition losses"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 391,
      "preview": "--- page 26 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 393
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 395,
      "preview": "|  Nutrient Absorption Sites | Mediator Release Sites  |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 396,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 397,
      "preview": "|  **Duodenum/Proximal Jejunum** | **Stomach**  |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 398,
      "preview": "|  - macronutrients | - gastrin  |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 399,
      "preview": "|  - iron | - ghrelin  |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 400,
      "preview": "|  - folate | **Duodenum**  |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 401,
      "preview": "|  - calcium | - cholecystokinin  |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 402,
      "preview": "|  - vitamins/minerals | - secretin  |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 403,
      "preview": "|  **Jejunum/Proximal Ileum** | **GIP**  |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 404,
      "preview": "|  - macronutrients | - VIP  |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 405,
      "preview": "|  - calcium | **Jejunum/Ileum**  |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 406,
      "preview": "|  - vitamins/minerals | - neurotensin  |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 407,
      "preview": "|  **Distal Ileum** | **Distal Ileum/Colon**  |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 408,
      "preview": "|  - bile salts | - peptide YY  |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 409,
      "preview": "|  - vitamin B12 | - GLP-1  |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 410,
      "preview": "|  - SCFA | - GLP-2  |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 411,
      "preview": "|  **Colon** |   |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 412,
      "preview": "|  - SCFA |   |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 413,
      "preview": "|  - minerals |   |"
    },
    {
      "type": "table",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 414,
      "preview": "|  - vitamin K |   |"
    },
    {
      "type": "image",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 416,
      "content": "![img-18.jpeg](images/4c7f034388bc031e.png)"
    },
    {
      "type": "image",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 418,
      "content": "![img-19.jpeg](images/ce657b2ee5d99ffa.png)"
    },
    {
      "type": "text",
      "section": "**Consider Site Specific Effects of Intestinal Resection for GI Function (and Stoma Losses) and GI Hormones**",
      "line": 420,
      "preview": "--- page 27 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 422
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 424,
      "preview": "- PN considerations to compensate for high losses in proximal ostomies"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 425,
      "preview": "- Fluid"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 426,
      "preview": "- Sodium; patients will not grow until adequately supplemented with sodium. Recommend following urin"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 427,
      "preview": "- Potassium"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 428,
      "preview": "- Bicarbonate; incompatible with PN so replaced as acetate in PN; in end stage liver disease may hav"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 429,
      "preview": "- Zinc"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 430,
      "preview": "- Iron; increased needs in ex-preterm, with chronic GI blood loss and extensive proximal small bowel"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 431,
      "preview": "- Copper; standard supplementation may be inadequate"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Surgery \\& Ostomies",
      "line": 433,
      "preview": "--- page 28 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Malnutrition in Pediatric Chronic Liver Disease",
      "line": 435
    },
    {
      "type": "table",
      "section": "Malnutrition in Pediatric Chronic Liver Disease",
      "line": 437,
      "preview": "|  Decreased energy intake | Anorexia"
    },
    {
      "type": "text",
      "section": "Malnutrition in Pediatric Chronic Liver Disease",
      "line": 438,
      "preview": "Changes in taste perception"
    },
    {
      "type": "text",
      "section": "Malnutrition in Pediatric Chronic Liver Disease",
      "line": 439,
      "preview": "Early satiety"
    },
    {
      "type": "table",
      "section": "Malnutrition in Pediatric Chronic Liver Disease",
      "line": 440,
      "preview": "Nausea / vomiting  |"
    },
    {
      "type": "table",
      "section": "Malnutrition in Pediatric Chronic Liver Disease",
      "line": 441,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Malnutrition in Pediatric Chronic Liver Disease",
      "line": 442,
      "preview": "|  Increased energy intake | Increased energy requirement up to 150\\% EAR"
    },
    {
      "type": "text",
      "section": "Malnutrition in Pediatric Chronic Liver Disease",
      "line": 443,
      "preview": "Hypermetabolic state in end-stage liver disease"
    },
    {
      "type": "text",
      "section": "Malnutrition in Pediatric Chronic Liver Disease",
      "line": 444,
      "preview": "Sequelae of CLD (i.e., peritonitis, variceal bleeding)"
    },
    {
      "type": "table",
      "section": "Malnutrition in Pediatric Chronic Liver Disease",
      "line": 445,
      "preview": "Increased pro-inflammatory cytokines  |"
    },
    {
      "type": "table",
      "section": "Malnutrition in Pediatric Chronic Liver Disease",
      "line": 446,
      "preview": "|  Endocrine dysfunction | Impaired GH / IGF-1 axis"
    },
    {
      "type": "table",
      "section": "Malnutrition in Pediatric Chronic Liver Disease",
      "line": 447,
      "preview": "Decreased IGF-1 formation  |"
    },
    {
      "type": "table",
      "section": "Malnutrition in Pediatric Chronic Liver Disease",
      "line": 448,
      "preview": "|  Malabsorption and disordered substrate metabolism | Carbohydrate - hypoglycemia from decreased gl"
    },
    {
      "type": "text",
      "section": "Malnutrition in Pediatric Chronic Liver Disease",
      "line": 449,
      "preview": "Proteins - increased protein catabolism, impaired protein synthesis"
    },
    {
      "type": "table",
      "section": "Malnutrition in Pediatric Chronic Liver Disease",
      "line": 450,
      "preview": "Fats - malabsorption from decreased bile delivery to small bowel, unconjugation of bile salts with b"
    },
    {
      "type": "text",
      "section": "Malnutrition in Pediatric Chronic Liver Disease",
      "line": 452,
      "preview": "--- page 29 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Liver Disease",
      "line": 454
    },
    {
      "type": "text",
      "section": "Liver Disease",
      "line": 456,
      "preview": "- Supplement"
    },
    {
      "type": "text",
      "section": "Liver Disease",
      "line": 457,
      "preview": "- Zinc (if deficient)"
    },
    {
      "type": "text",
      "section": "Liver Disease",
      "line": 458,
      "preview": "- Potassium (especially if on diuretics)"
    },
    {
      "type": "text",
      "section": "Liver Disease",
      "line": 459,
      "preview": "- Fat soluble vitamins D, E, K (if deficient)"
    },
    {
      "type": "text",
      "section": "Liver Disease",
      "line": 460,
      "preview": "- Protein (if hypoalbuminemic and not encephalopathic)"
    },
    {
      "type": "text",
      "section": "Liver Disease",
      "line": 461,
      "preview": "- Encephalopathy"
    },
    {
      "type": "text",
      "section": "Liver Disease",
      "line": 462,
      "preview": "- Reduce protein"
    },
    {
      "type": "text",
      "section": "Liver Disease",
      "line": 463,
      "preview": "- Monitor ammonia"
    },
    {
      "type": "text",
      "section": "Liver Disease",
      "line": 464,
      "preview": "- Cholestasis"
    },
    {
      "type": "text",
      "section": "Liver Disease",
      "line": 465,
      "preview": "- Restrict copper, manganese since they are secreted in bile"
    },
    {
      "type": "text",
      "section": "Liver Disease",
      "line": 466,
      "preview": "- Adjust lipids: consider fish oil lipid emulsion (Omegaven ${ }^{\\circledR}$ )"
    },
    {
      "type": "text",
      "section": "Liver Disease",
      "line": 467,
      "preview": "- Immunosuppressant medications can affect nutritional status"
    },
    {
      "type": "text",
      "section": "Liver Disease",
      "line": 469,
      "preview": "--- page 30 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Vitamins: Lab Markers and Dosing Recommendations",
      "line": 471
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Vitamin A",
      "line": 473
    },
    {
      "type": "text",
      "section": "Vitamin A",
      "line": 475,
      "preview": "Laboratory Markers"
    },
    {
      "type": "text",
      "section": "Vitamin A",
      "line": 476,
      "preview": "Serum retinol level"
    },
    {
      "type": "text",
      "section": "Vitamin A",
      "line": 477,
      "preview": "If available RDR"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Recommendations",
      "line": 479
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 481,
      "preview": "1000 IU/kg/day, up to"
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 482,
      "preview": "25,000 IU of water miscible formulations"
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 484,
      "preview": "- $<10 \\mathrm{~kg}$ : start with 5000 IU/day"
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 485,
      "preview": "- $>10 \\mathrm{~kg}$ : start with 10,000 IU/day"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Vitamin D",
      "line": 488
    },
    {
      "type": "text",
      "section": "Vitamin D",
      "line": 490,
      "preview": "Laboratory Markers"
    },
    {
      "type": "text",
      "section": "Vitamin D",
      "line": 491,
      "preview": "Serum 25-OHD"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Recommendations",
      "line": 493
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 495,
      "preview": "Cholecalciferol"
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 497,
      "preview": "- Weight $>40 \\mathrm{~kg}$"
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 498,
      "preview": "- Serum level <10 $\\mathrm{ng} / \\mathrm{mL}: 5000 \\mathrm{IU} /$ day"
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 499,
      "preview": "- Serum level 11-19 $\\mathrm{ng} / \\mathrm{mL}: 4000 \\mathrm{IU} /$ day"
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 500,
      "preview": "- Serum level 20-29 $\\mathrm{ng} / \\mathrm{mL}: 3000 \\mathrm{IU} /$ day"
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 501,
      "preview": "- Weight $<40 \\mathrm{~kg}$"
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 502,
      "preview": "-120-200 IU/kg"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Vitamin E",
      "line": 505
    },
    {
      "type": "text",
      "section": "Vitamin E",
      "line": 507,
      "preview": "Laboratory Markers"
    },
    {
      "type": "text",
      "section": "Vitamin E",
      "line": 508,
      "preview": "Serum tocopherol level"
    },
    {
      "type": "text",
      "section": "Vitamin E",
      "line": 509,
      "preview": "If available"
    },
    {
      "type": "text",
      "section": "Vitamin E",
      "line": 510,
      "preview": "$\\alpha$-tocopherol/total"
    },
    {
      "type": "text",
      "section": "Vitamin E",
      "line": 511,
      "preview": "lipids ratio"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Recommendations",
      "line": 513
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 515,
      "preview": "D- $\\alpha$-tocopherol"
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 516,
      "preview": "polyethylene glycol 1000"
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 517,
      "preview": "succinate (TPGS) 15-25"
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 518,
      "preview": "IU/kg/day"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Vitamin K",
      "line": 520
    },
    {
      "type": "text",
      "section": "Vitamin K",
      "line": 522,
      "preview": "Laboratory Markers"
    },
    {
      "type": "text",
      "section": "Vitamin K",
      "line": 523,
      "preview": "PT/INR"
    },
    {
      "type": "text",
      "section": "Vitamin K",
      "line": 524,
      "preview": "If available PIVKA-II"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Recommendations",
      "line": 526
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 528,
      "preview": "2.5-5 mg/day 2-7 times weekly; 1-10 mg intravenous as needed"
    },
    {
      "type": "text",
      "section": "Recommendations",
      "line": 530,
      "preview": "--- page 31 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nutritional Needs of Children With CLD Before and After Liver Transplant",
      "line": 532
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Liver Transplant",
      "line": 534
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Before",
      "line": 536
    },
    {
      "type": "heading",
      "level": 2,
      "section": "ENERGY INTAKE",
      "line": 538
    },
    {
      "type": "text",
      "section": "ENERGY INTAKE",
      "line": 540,
      "preview": "- 130-150\\% EAR"
    },
    {
      "type": "text",
      "section": "ENERGY INTAKE",
      "line": 542,
      "preview": "CARBOHYDRATES"
    },
    {
      "type": "text",
      "section": "ENERGY INTAKE",
      "line": 544,
      "preview": "- 15-20 g/kg/day given as glucose polymers"
    },
    {
      "type": "text",
      "section": "ENERGY INTAKE",
      "line": 546,
      "preview": "PROTEINS"
    },
    {
      "type": "text",
      "section": "ENERGY INTAKE",
      "line": 548,
      "preview": "- 3-4 g/kg/day; if acutely encephalopathic may temporarily restrict to $<2 \\mathrm{~g} / \\mathrm{kg}"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "FATS",
      "line": 551
    },
    {
      "type": "text",
      "section": "FATS",
      "line": 553,
      "preview": "- 8 g/kg/day, with 30-50\\% as MCT"
    },
    {
      "type": "text",
      "section": "FATS",
      "line": 554,
      "preview": "- Infants can receive formula containing up to $75 \\%$ MCT; higher MCT content may result in essenti"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "After",
      "line": 557
    },
    {
      "type": "heading",
      "level": 2,
      "section": "ENERGY INTAKE",
      "line": 559
    },
    {
      "type": "text",
      "section": "ENERGY INTAKE",
      "line": 561,
      "preview": "- 120\\% EAR"
    },
    {
      "type": "text",
      "section": "ENERGY INTAKE",
      "line": 563,
      "preview": "CARBOHYDRATES"
    },
    {
      "type": "text",
      "section": "ENERGY INTAKE",
      "line": 565,
      "preview": "- 6-8 g/kg/day given as glucose polymers"
    },
    {
      "type": "text",
      "section": "ENERGY INTAKE",
      "line": 567,
      "preview": "PROTEINS"
    },
    {
      "type": "text",
      "section": "ENERGY INTAKE",
      "line": 569,
      "preview": "- 2.5-3 g/kg/day"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "FATS",
      "line": 572
    },
    {
      "type": "text",
      "section": "FATS",
      "line": 574,
      "preview": "- 5-6 g/kg/day LCT"
    },
    {
      "type": "text",
      "section": "FATS",
      "line": 575,
      "preview": "- Children receiving high MCT-containing supplementation pretransplant can transition to standard fo"
    },
    {
      "type": "text",
      "section": "FATS",
      "line": 577,
      "preview": "--- page 32 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 579
    },
    {
      "type": "table",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 581,
      "preview": "|  Immunosuppressant | Nutritional Side-Effects  |"
    },
    {
      "type": "table",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 582,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 583,
      "preview": "|  Calcineurin inhibitors (FK, tacrolimus, cyclosporine) | Hyperlipidemia, Hyperglycemia"
    },
    {
      "type": "text",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 584,
      "preview": "Hypomagnesemia, Hyperkalemia"
    },
    {
      "type": "text",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 585,
      "preview": "Hypertension"
    },
    {
      "type": "table",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 586,
      "preview": "Avoid grapefruit  |"
    },
    {
      "type": "table",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 587,
      "preview": "|  Corticosteroids (prednisone, methylprednisolone) | Hyperglycemia, Hyperlipidemia"
    },
    {
      "type": "text",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 588,
      "preview": "Sodium retention, Hypertension"
    },
    {
      "type": "text",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 589,
      "preview": "Increased appetite, Weight gain"
    },
    {
      "type": "text",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 590,
      "preview": "Muscle wasting"
    },
    {
      "type": "text",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 591,
      "preview": "Peptic ulcer disease"
    },
    {
      "type": "text",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 592,
      "preview": "Impaired wound healing"
    },
    {
      "type": "table",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 593,
      "preview": "Electrolyte disturbances  |"
    },
    {
      "type": "table",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 594,
      "preview": "|  Mycophenolate (MMF) | Diarrhea, Nausea  |"
    },
    {
      "type": "table",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 595,
      "preview": "|  Azathioprine | Nausea, vomiting, sore throat, altered taste acuity  |"
    },
    {
      "type": "table",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 596,
      "preview": "|  Sirolimus | Hyperlipidemia, GI symptoms  |"
    },
    {
      "type": "text",
      "section": "Nutritional Side-Effects of Immunosuppressive Meds",
      "line": 598,
      "preview": "--- page 33 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Renal Disease",
      "line": 600
    },
    {
      "type": "text",
      "section": "Renal Disease",
      "line": 602,
      "preview": "- When to consider PN"
    },
    {
      "type": "text",
      "section": "Renal Disease",
      "line": 603,
      "preview": "- Peritoneal dialysis complicated by ileus or peritonitis"
    },
    {
      "type": "text",
      "section": "Renal Disease",
      "line": 604,
      "preview": "- Critically ill patients on hemodialysis"
    },
    {
      "type": "text",
      "section": "Renal Disease",
      "line": 605,
      "preview": "- Severe malnutrition, intolerance of enteral feeds"
    },
    {
      "type": "text",
      "section": "Renal Disease",
      "line": 606,
      "preview": "- Intestinal obstruction (mechanical or pseudo-obstruction)"
    },
    {
      "type": "text",
      "section": "Renal Disease",
      "line": 607,
      "preview": "- Acute Kidney Injury (AKI)"
    },
    {
      "type": "text",
      "section": "Renal Disease",
      "line": 608,
      "preview": "- Fluid intake is often reduced"
    },
    {
      "type": "text",
      "section": "Renal Disease",
      "line": 609,
      "preview": "- Volume available for PN can impact on caloric intake"
    },
    {
      "type": "text",
      "section": "Renal Disease",
      "line": 610,
      "preview": "- Protein intake often restricted to meet minimum requirements"
    },
    {
      "type": "text",
      "section": "Renal Disease",
      "line": 611,
      "preview": "- Electrolytes based on serum levels"
    },
    {
      "type": "text",
      "section": "Renal Disease",
      "line": 613,
      "preview": "--- page 34 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Renal Disease - Cont'd",
      "line": 615
    },
    {
      "type": "text",
      "section": "Renal Disease - Cont'd",
      "line": 617,
      "preview": "- On dialysis"
    },
    {
      "type": "text",
      "section": "Renal Disease - Cont'd",
      "line": 618,
      "preview": "- Protein losses are increased by dialysis"
    },
    {
      "type": "text",
      "section": "Renal Disease - Cont'd",
      "line": 619,
      "preview": "- Dialysis removes excess urea"
    },
    {
      "type": "text",
      "section": "Renal Disease - Cont'd",
      "line": 620,
      "preview": "- Increase fluid, calorie, and protein provision"
    },
    {
      "type": "text",
      "section": "Renal Disease - Cont'd",
      "line": 621,
      "preview": "- No longer need to restrict or reduce protein provision"
    },
    {
      "type": "text",
      "section": "Renal Disease - Cont'd",
      "line": 623,
      "preview": "--- page 35 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Renal Disease Nutrient Recommendations",
      "line": 625
    },
    {
      "type": "table",
      "section": "Renal Disease Nutrient Recommendations",
      "line": 627,
      "preview": "|  Restriction may be required | Supplementation may be required  |"
    },
    {
      "type": "table",
      "section": "Renal Disease Nutrient Recommendations",
      "line": 628,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Renal Disease Nutrient Recommendations",
      "line": 629,
      "preview": "|  Deduct dialysate glucose when calculating glucose infusion rate (GIR) | Protein"
    },
    {
      "type": "table",
      "section": "Renal Disease Nutrient Recommendations",
      "line": 630,
      "preview": "(increased losses with dialysis)  |"
    },
    {
      "type": "table",
      "section": "Renal Disease Nutrient Recommendations",
      "line": 631,
      "preview": "|  Total fluids (based on fluid status and dialysis settings) | Alkali due to increased losses in 'n"
    },
    {
      "type": "table",
      "section": "Renal Disease Nutrient Recommendations",
      "line": 632,
      "preview": "|  Sodium (give in small amounts due to diminished excretion) | Sodium due to increased losses in 'n"
    },
    {
      "type": "table",
      "section": "Renal Disease Nutrient Recommendations",
      "line": 633,
      "preview": "|  Potassium (give in small amounts due to diminished excretion) | Potassium"
    },
    {
      "type": "table",
      "section": "Renal Disease Nutrient Recommendations",
      "line": 634,
      "preview": "(if on diuretics or depending on dialysate)  |"
    },
    {
      "type": "table",
      "section": "Renal Disease Nutrient Recommendations",
      "line": 635,
      "preview": "|  Phosphorous (give in small amounts due to diminished excretion) |   |"
    },
    {
      "type": "table",
      "section": "Renal Disease Nutrient Recommendations",
      "line": 636,
      "preview": "|  Vitamin C to <100 mg/day in pts with hyperoxaluria |   |"
    },
    {
      "type": "table",
      "section": "Renal Disease Nutrient Recommendations",
      "line": 637,
      "preview": "|  Lipids in patients with hyperlipidemia of renal failure |   |"
    },
    {
      "type": "text",
      "section": "Renal Disease Nutrient Recommendations",
      "line": 639,
      "preview": "--- page 36 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 641
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 643,
      "preview": "|  Age Group | Pre-Dialysis |  | Hemodialysis |  | Peritoneal Dialysis |   |"
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 644,
      "preview": "| --- | --- | --- | --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 645,
      "preview": "|   | Energy"
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 646,
      "preview": "Kcal/kg/d | Protein"
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 647,
      "preview": "g/kg/d | Energy"
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 648,
      "preview": "Kcal/kg/d | Protein"
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 649,
      "preview": "g/kg/d | Energy"
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 650,
      "preview": "Kcal/kg/d | Protein"
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 651,
      "preview": "g/kg/d  |"
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 652,
      "preview": "|  $0-6 \\mathrm{~m}$ | $100-110$ | $1.5-2.2$ | $100-110$ | 1.6 | $100-110$ | 1.8  |"
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 653,
      "preview": "|  $6-12 \\mathrm{~m}$ | $95-105$ | $1.2-1.7$ | $95-105$ | 1.3 | $95-105$ | 1.5  |"
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 654,
      "preview": "|  $1-3 \\mathrm{y}$ | 90 | $1.05-1.5$ | 90 | 1.15 | 90 | 1.3  |"
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 655,
      "preview": "|  $4-10 \\mathrm{y}$ | 70 | $0.95-1.35$ | 70 | $1.05-1.6$ | 70 | $1.1-2.0$  |"
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 656,
      "preview": "|  $11-14 \\mathrm{y}$ (boys) | 55 | $0.95-1.35$ | 55 | $1.05-1.4$ | 55 | $1.1-1.8$  |"
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 657,
      "preview": "|  $11-14 \\mathrm{y}$ (girls) | 47 | $0.95-1.35$ | 47 | $1.05-1.4$ | 47 | $1.1-1.8$  |"
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 658,
      "preview": "|  $15-18 \\mathrm{y}$ (boys | 45 | $0.85-1.2$ | 45 | $0.95-1.3$ | 45 | $1.0-1.5$  |"
    },
    {
      "type": "table",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 659,
      "preview": "|  $15-18$ (girls) | 40 | $0.85-1.2$ | 40 | $0.95-1.2$ | 40 | $1.0-1.5$  |"
    },
    {
      "type": "text",
      "section": "Estimated Energy and Protein Requirements in Children with Renal Disease",
      "line": 661,
      "preview": "--- page 37 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Micronutrients in AKI: Energy",
      "line": 663
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Energy",
      "line": 665,
      "preview": "|  Macronutrient | AKI, no RRT | CRRT | PIRRT | HD | PD  |"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Energy",
      "line": 666,
      "preview": "| --- | --- | --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Energy",
      "line": 667,
      "preview": "|  Energy | Dictated by disease state, malnutrition, and illness severity |  |  |  |   |"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Energy",
      "line": 668,
      "preview": "|  Key considerations | N/A | - High removal rates of levocarnitine may influence metabolism of free"
    },
    {
      "type": "text",
      "section": "Micronutrients in AKI: Energy",
      "line": 669,
      "preview": "- Largely dependent o use of citrate-based anticoagulation and dextrose solutions used within respec"
    },
    {
      "type": "text",
      "section": "Micronutrients in AKI: Energy",
      "line": 670,
      "preview": "- Larger patients likely receive more significant exposure"
    },
    {
      "type": "text",
      "section": "Micronutrients in AKI: Energy",
      "line": 671,
      "preview": "- May be CRRT dose dependent. Higher dose may clear more nonnutritive fluids into effluent than lowe"
    },
    {
      "type": "text",
      "section": "Micronutrients in AKI: Energy",
      "line": 672,
      "preview": "- Glucose-free replacement fluids may lead to energy removal"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Energy",
      "line": 673,
      "preview": "- Hyperosmolar, hyperglycemic states may contribute to energy deficit | N/A | - Dextrose is present "
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Energy",
      "line": 674,
      "preview": "- Monitor weight trends and adjust nutrition support accordingly |   |"
    },
    {
      "type": "text",
      "section": "Micronutrients in AKI: Energy",
      "line": 676,
      "preview": "Note: Suggestions within this table are initial recommendations that should be titrated based on pat"
    },
    {
      "type": "text",
      "section": "Micronutrients in AKI: Energy",
      "line": 678,
      "preview": "--- page 38 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Micronutrients in AKI: Protein",
      "line": 680
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Protein",
      "line": 682,
      "preview": "|  Macronutrient | AKI, no RRT | CRRT | PIRRT | HD | PD  |"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Protein",
      "line": 683,
      "preview": "| --- | --- | --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Protein",
      "line": 684,
      "preview": "|  Protein | DRI /"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Protein",
      "line": 685,
      "preview": "age minimum | $\\geq 2.5 \\mathrm{~g} / \\mathrm{kg} /$ day protein or ASPEN/ age + additional $10 \\%-2"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Protein",
      "line": 686,
      "preview": "age $+0.1 \\mathrm{~g} / \\mathrm{kg} /$ day | ASPEN /"
    },
    {
      "type": "text",
      "section": "Micronutrients in AKI: Protein",
      "line": 687,
      "preview": "age $+0.3$"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Protein",
      "line": 688,
      "preview": "$\\mathrm{g} / \\mathrm{kg} /$ day  |"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Protein",
      "line": 689,
      "preview": "|  Key considerations | - Temporary protein restrictions may be implemented if AKI recovery expected"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Protein",
      "line": 690,
      "preview": "- Inability to obtain dialysis access may limit ability to provide goal protein intake | - No expect"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Protein",
      "line": 691,
      "preview": "- $2.5 \\mathrm{~g} / \\mathrm{kg} /$ day is extrapolated from adults | - May require less protein tha"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Protein",
      "line": 692,
      "preview": "- If HD frequency expected to be higher, adjust for increased frequency | - Values are extrapolated "
    },
    {
      "type": "text",
      "section": "Micronutrients in AKI: Protein",
      "line": 694,
      "preview": "Note: Suggestions within this table are initial recommendations that should be titrated based on pat"
    },
    {
      "type": "text",
      "section": "Micronutrients in AKI: Protein",
      "line": 696,
      "preview": "--- page 39 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Micronutrients in AKI: Fluid",
      "line": 698
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Fluid",
      "line": 700,
      "preview": "|  Macronutrient | AKI, no RRT | CRRT | PIRRT | HD | PD  |"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Fluid",
      "line": 701,
      "preview": "| --- | --- | --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Fluid",
      "line": 702,
      "preview": "|  Fluid | Largely dependent on responsiveness to diuretics | - Unrestricted"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Fluid",
      "line": 703,
      "preview": "- May be temporarily restricted around initial start | Largely dependent on length of treatment | - "
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Fluid",
      "line": 704,
      "preview": "- Limit myocardial stunning; may be lower in hemodynamically unstable patients | Unpredictable  |"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Fluid",
      "line": 705,
      "preview": "|  Key considerations | - Follow I/Os and fluid balance goals accounting for urine output, volume of"
    },
    {
      "type": "table",
      "section": "Micronutrients in AKI: Fluid",
      "line": 706,
      "preview": "- Concentrate nutrition support when able if not achieving fluid balance goals |  |  |  |   |"
    },
    {
      "type": "text",
      "section": "Micronutrients in AKI: Fluid",
      "line": 708,
      "preview": "Note: Suggestions within this table are initial recommendations that should be titrated based on pat"
    },
    {
      "type": "text",
      "section": "Micronutrients in AKI: Fluid",
      "line": 710,
      "preview": "--- page 40 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Inborn Errors of Metabolism",
      "line": 712
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism",
      "line": 714,
      "preview": "- PN should be initiated quickly during metabolic stressors"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism",
      "line": 715,
      "preview": "- Promote anabolism"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism",
      "line": 716,
      "preview": "- Diminish catabolism"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism",
      "line": 717,
      "preview": "- Use PN short-term and start enteral nutrition (EN) as soon as clinically feasible"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism",
      "line": 718,
      "preview": "- Metabolic parameters should be monitored closely with adjustment of type and amount of protein whe"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism",
      "line": 719,
      "preview": "- Common metabolic stressors"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism",
      "line": 720,
      "preview": "- Trauma"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism",
      "line": 721,
      "preview": "- Infection"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism",
      "line": 722,
      "preview": "- Burns"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism",
      "line": 723,
      "preview": "- Altered mental status"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism",
      "line": 724,
      "preview": "- Gastrointestinal (pancreatitis, ileus)"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism",
      "line": 725,
      "preview": "- Essential fatty acid deficiency"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism",
      "line": 727,
      "preview": "--- page 41 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Inborn Errors of Metabolism: Phenylketonuria (PKU)",
      "line": 729
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Phenylketonuria (PKU)",
      "line": 731,
      "preview": "- Hypercatabolism occurs during stress"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Phenylketonuria (PKU)",
      "line": 732,
      "preview": "- Parallels the extent of infection/injury"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Phenylketonuria (PKU)",
      "line": 733,
      "preview": "- Goal is prevention of prolonged phenylalanine (PHE) elevation"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Phenylketonuria (PKU)",
      "line": 734,
      "preview": "- Interventions to depress catabolic response"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Phenylketonuria (PKU)",
      "line": 735,
      "preview": "- PN as bridge to enteral nutrition"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Phenylketonuria (PKU)",
      "line": 736,
      "preview": "- PHE-free parenteral amino-acid solution with some standard parenteral amino acids"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Phenylketonuria (PKU)",
      "line": 737,
      "preview": "- Not commercially available"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Phenylketonuria (PKU)",
      "line": 738,
      "preview": "- Needs to be made by a compounding pharmacy"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Phenylketonuria (PKU)",
      "line": 740,
      "preview": "--- page 42 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Inborn Errors of Metabolism: Mitochondrial Disorders",
      "line": 742
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Mitochondrial Disorders",
      "line": 744,
      "preview": "- Avoid exposure to PN if possible"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Mitochondrial Disorders",
      "line": 745,
      "preview": "- High-glucose diet is a metabolic challenge for impaired oxidative phosphorylation"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Mitochondrial Disorders",
      "line": 746,
      "preview": "- Glucose oxidation is largely aerobic in the liver"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Mitochondrial Disorders",
      "line": 747,
      "preview": "- High lipid/low carbohydrate diet recommended in Complex I deficiency"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Mitochondrial Disorders",
      "line": 748,
      "preview": "- Carnitine supplementation is recommended in patients with secondary carnitine deficiency"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Mitochondrial Disorders",
      "line": 749,
      "preview": "- Dose of carnitine needed is higher than nutritional doses"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Mitochondrial Disorders",
      "line": 750,
      "preview": "- Carnitine to be administered separately from PN to ensure adequate provision"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Mitochondrial Disorders",
      "line": 752,
      "preview": "--- page 43 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Inborn Errors of Metabolism: Propionic Acidemia and Methylmalonic Acidemia (MMA)",
      "line": 754
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Propionic Acidemia and Methylmalonic Acidemia (MMA)",
      "line": 756,
      "preview": "Management of acute crisis"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Propionic Acidemia and Methylmalonic Acidemia (MMA)",
      "line": 758,
      "preview": "- Remove sources of isoleucine (ILE), methionine (MET), threonine (THR), valine (VAL)"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Propionic Acidemia and Methylmalonic Acidemia (MMA)",
      "line": 759,
      "preview": "- IV glucose and electrolytes: $150 \\mathrm{~mL} / \\mathrm{kg}$; glucose infusion rate (GIR): $10 \\m"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Propionic Acidemia and Methylmalonic Acidemia (MMA)",
      "line": 760,
      "preview": "- Treat metabolic acidosis and maintain normal sodium levels"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Propionic Acidemia and Methylmalonic Acidemia (MMA)",
      "line": 761,
      "preview": "- Add lipids $2-3 \\mathrm{~g} / \\mathrm{kg} /$ day to achieve total caloric goal of 120-150 $\\mathrm"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Propionic Acidemia and Methylmalonic Acidemia (MMA)",
      "line": 762,
      "preview": "- Intravenous L-carnitine 100-300 mg/kg/day to help improve clearance"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Propionic Acidemia and Methylmalonic Acidemia (MMA)",
      "line": 764,
      "preview": "--- page 44 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Inborn Errors of Metabolism: Propionic Acidemia and MMA - Cont'd",
      "line": 766
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Propionic Acidemia and MMA - Cont'd",
      "line": 768,
      "preview": "Management of acute crisis"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Propionic Acidemia and MMA - Cont'd",
      "line": 770,
      "preview": "- Combination PN (and EN) within 24 - 48 hours to prevent ILE, MET, THR and VAL deficiency"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Propionic Acidemia and MMA - Cont'd",
      "line": 771,
      "preview": "- Initiate protein at $0.5 \\mathrm{~g} / \\mathrm{kg} /$ day and increase as tolerated not exceeding "
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Propionic Acidemia and MMA - Cont'd",
      "line": 772,
      "preview": "- Monitor daily plasma amino acids until stable"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Propionic Acidemia and MMA - Cont'd",
      "line": 773,
      "preview": "- Peripheral PN will not provide sufficient energy for anabolism"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Propionic Acidemia and MMA - Cont'd",
      "line": 775,
      "preview": "--- page 45 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Inborn Errors of Metabolism: Maple Syrup Urine Disease (MSUD)",
      "line": 777
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Maple Syrup Urine Disease (MSUD)",
      "line": 779,
      "preview": "- Comatose or Neurologically compromised patients"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Maple Syrup Urine Disease (MSUD)",
      "line": 780,
      "preview": "- Goal calories"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Maple Syrup Urine Disease (MSUD)",
      "line": 782,
      "preview": "Infants: 120 - 140 kcal/kg/day"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Maple Syrup Urine Disease (MSUD)",
      "line": 783,
      "preview": "Children: 80 - 100 kcal/kg/day"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Maple Syrup Urine Disease (MSUD)",
      "line": 784,
      "preview": "Adults: 40 - 45 kcal/kg/day"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Maple Syrup Urine Disease (MSUD)",
      "line": 786,
      "preview": "- Add insulin to treat hyperglycemia (need anabolic GIR)"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Maple Syrup Urine Disease (MSUD)",
      "line": 788,
      "preview": "--- page 46 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Inborn Errors of Metabolism: MSUD - Cont'd",
      "line": 790
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: MSUD - Cont'd",
      "line": 792,
      "preview": "- Use branch chain amino acid (BCAA)-free solution and monitor plasma amino acids"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: MSUD - Cont'd",
      "line": 793,
      "preview": "- Neonates: give $2.5-3 \\mathrm{~g} / \\mathrm{kg} /$ day protein"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: MSUD - Cont'd",
      "line": 794,
      "preview": "- Plasma ILE/VAL decrease more rapidly then, LEU"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: MSUD - Cont'd",
      "line": 795,
      "preview": "- Add ILE/VAL supplement to PN at lower limits of recommended intake"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: MSUD - Cont'd",
      "line": 796,
      "preview": "- Add LEU when plasma LEU reaches $200 \\mu \\mathrm{~mol} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: MSUD - Cont'd",
      "line": 797,
      "preview": "- Not commercially available, needs to be made by a compounding pharmacy"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: MSUD - Cont'd",
      "line": 798,
      "preview": "- Normalization of all 3 BCAA usually happens in 48 - 72 hours"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: MSUD - Cont'd",
      "line": 799,
      "preview": "- When able to tolerate enteral feeds start BCAA-free food"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: MSUD - Cont'd",
      "line": 801,
      "preview": "--- page 47 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Inborn Errors of Metabolism: Urea Cycle Disorders (UCDs)",
      "line": 803
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Urea Cycle Disorders (UCDs)",
      "line": 805,
      "preview": "- Provide abundant calories with high glucose and lipids to minimize catabolism"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Urea Cycle Disorders (UCDs)",
      "line": 806,
      "preview": "- Reduce nitrogen load"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Urea Cycle Disorders (UCDs)",
      "line": 807,
      "preview": "- Restrict nitrogen intake"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Urea Cycle Disorders (UCDs)",
      "line": 808,
      "preview": "- Activate alternate pathways for nitrogen excretion"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Urea Cycle Disorders (UCDs)",
      "line": 809,
      "preview": "- Arginine supplementation needed"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Urea Cycle Disorders (UCDs)",
      "line": 810,
      "preview": "- Available as a separate IV infusion for this purpose"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Urea Cycle Disorders (UCDs)",
      "line": 811,
      "preview": "- Monitor closely for catabolic stressors and risk factors for hyperammonemia"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Urea Cycle Disorders (UCDs)",
      "line": 812,
      "preview": "- Birth"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Urea Cycle Disorders (UCDs)",
      "line": 813,
      "preview": "- Illness"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Urea Cycle Disorders (UCDs)",
      "line": 814,
      "preview": "- Excess protein intake"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Urea Cycle Disorders (UCDs)",
      "line": 815,
      "preview": "- Surgery"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: Urea Cycle Disorders (UCDs)",
      "line": 817,
      "preview": "--- page 48 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Inborn Errors of Metabolism: UCDs - Cont'd",
      "line": 819
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: UCDs - Cont'd",
      "line": 821,
      "preview": "- Early consideration of parenteral support, if emesis is present to diminish catabolic sequelae"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: UCDs - Cont'd",
      "line": 822,
      "preview": "- High parenteral energy provision"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: UCDs - Cont'd",
      "line": 823,
      "preview": "- 80 - 100 kcal/kg/day for infants"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: UCDs - Cont'd",
      "line": 824,
      "preview": "- 10\\% dextrose and ILE with glucose infusion rate of 6 - 8 $\\mathrm{mg} / \\mathrm{kg} / \\mathrm{min"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: UCDs - Cont'd",
      "line": 825,
      "preview": "- For persistent catabolism use 10 - 35\\% dextrose along with insulin (to stop catabolism of glucose"
    },
    {
      "type": "text",
      "section": "Inborn Errors of Metabolism: UCDs - Cont'd",
      "line": 827,
      "preview": "--- page 49 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Short Bowel Syndrome / Intestinal Failure",
      "line": 829
    },
    {
      "type": "text",
      "section": "Short Bowel Syndrome / Intestinal Failure",
      "line": 831,
      "preview": "- Pediatric Intestinal Failure as defined by NASPGHAN 2017 as, \"The need for PN for > 60 days due to"
    },
    {
      "type": "text",
      "section": "Short Bowel Syndrome / Intestinal Failure",
      "line": 832,
      "preview": "- PN is needed to meet energy, fluid, and nutritional requirements when enteral nutrition (EN) is in"
    },
    {
      "type": "table",
      "section": "Short Bowel Syndrome / Intestinal Failure",
      "line": 834,
      "preview": "|  Diagnosis associated with intestinal failure and short bowel syndrome in infants (N=272) |   |"
    },
    {
      "type": "table",
      "section": "Short Bowel Syndrome / Intestinal Failure",
      "line": 835,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Short Bowel Syndrome / Intestinal Failure",
      "line": 836,
      "preview": "|  Diagnosis | N (\\%)  |"
    },
    {
      "type": "table",
      "section": "Short Bowel Syndrome / Intestinal Failure",
      "line": 837,
      "preview": "|  Necrotizing enterocolitis | 71 (26)  |"
    },
    {
      "type": "table",
      "section": "Short Bowel Syndrome / Intestinal Failure",
      "line": 838,
      "preview": "|  Gastroschisis | 44 (16)  |"
    },
    {
      "type": "table",
      "section": "Short Bowel Syndrome / Intestinal Failure",
      "line": 839,
      "preview": "|  Intestinal atresia (large/small) | 27 (10)  |"
    },
    {
      "type": "table",
      "section": "Short Bowel Syndrome / Intestinal Failure",
      "line": 840,
      "preview": "|  Volvulus | 24 (9)  |"
    },
    {
      "type": "table",
      "section": "Short Bowel Syndrome / Intestinal Failure",
      "line": 841,
      "preview": "|  Long segment Hirschsprung's disease | 11 (4)  |"
    },
    {
      "type": "table",
      "section": "Short Bowel Syndrome / Intestinal Failure",
      "line": 842,
      "preview": "|  Tufting or microvillus inclusion | 3 (1)  |"
    },
    {
      "type": "table",
      "section": "Short Bowel Syndrome / Intestinal Failure",
      "line": 843,
      "preview": "|  Other single diagnoses | 14 (5)  |"
    },
    {
      "type": "table",
      "section": "Short Bowel Syndrome / Intestinal Failure",
      "line": 844,
      "preview": "|  Unknown | 1  |"
    },
    {
      "type": "table",
      "section": "Short Bowel Syndrome / Intestinal Failure",
      "line": 845,
      "preview": "|  Multiple single diagnoses | 77928)  |"
    },
    {
      "type": "text",
      "section": "Short Bowel Syndrome / Intestinal Failure",
      "line": 847,
      "preview": "--- page 50 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "**Intestinal Failure Associated Liver Disease (IFALD)**",
      "line": 849
    },
    {
      "type": "text",
      "section": "**Intestinal Failure Associated Liver Disease (IFALD)**",
      "line": 851,
      "preview": "- IFALD is seen in up to 2/3rds of patients on long-term PN"
    },
    {
      "type": "text",
      "section": "**Intestinal Failure Associated Liver Disease (IFALD)**",
      "line": 852,
      "preview": "- IFALD is defined as *\"hepatobiliary dysfunction as a consequence of medical and surgical managemen"
    },
    {
      "type": "text",
      "section": "**Intestinal Failure Associated Liver Disease (IFALD)**",
      "line": 853,
      "preview": "- Many factors contribute to the development of IFALD"
    },
    {
      "type": "image",
      "section": "**Intestinal Failure Associated Liver Disease (IFALD)**",
      "line": 855,
      "content": "![img-20.jpeg](images/6609086828645fe4.png)"
    },
    {
      "type": "text",
      "section": "**Intestinal Failure Associated Liver Disease (IFALD)**",
      "line": 857,
      "preview": "Norsa L, *et al.* *Nutrients* 2018;10:664."
    },
    {
      "type": "text",
      "section": "**Intestinal Failure Associated Liver Disease (IFALD)**",
      "line": 859,
      "preview": "--- page 51 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "PN in Intestinal Failure",
      "line": 861
    },
    {
      "type": "text",
      "section": "PN in Intestinal Failure",
      "line": 863,
      "preview": "- Multifactorial etiology"
    },
    {
      "type": "text",
      "section": "PN in Intestinal Failure",
      "line": 864,
      "preview": "- Macronutrient excess promotes hepatic steatosis"
    },
    {
      "type": "text",
      "section": "PN in Intestinal Failure",
      "line": 865,
      "preview": "- High GIR result in increased insulin, triggering hepatic lipogenesis"
    },
    {
      "type": "text",
      "section": "PN in Intestinal Failure",
      "line": 866,
      "preview": "- Target required energy for disease state"
    },
    {
      "type": "text",
      "section": "PN in Intestinal Failure",
      "line": 867,
      "preview": "- Balance nonprotein calories: $75 \\%$ as carbohydrate, $25 \\%$ as fat"
    },
    {
      "type": "text",
      "section": "PN in Intestinal Failure",
      "line": 868,
      "preview": "- High cumulative infusion of amino acids may also play a role"
    },
    {
      "type": "text",
      "section": "PN in Intestinal Failure",
      "line": 869,
      "preview": "- Use of PN amino acid solutions designed for children to avoid nitrogen excess is advised"
    },
    {
      "type": "text",
      "section": "PN in Intestinal Failure",
      "line": 870,
      "preview": "- Blood urea nitrogen, acidosis, nitrogen balance and growth can be monitored"
    },
    {
      "type": "text",
      "section": "PN in Intestinal Failure",
      "line": 872,
      "preview": "--- page 52 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Lipid Emulsions and IFALD",
      "line": 874
    },
    {
      "type": "text",
      "section": "Lipid Emulsions and IFALD",
      "line": 876,
      "preview": "- Soy based intravenous lipid emulsions (ILE) contain high $\\omega-6$ long-chain polyunsaturated fat"
    },
    {
      "type": "text",
      "section": "Lipid Emulsions and IFALD",
      "line": 877,
      "preview": "- Discontinuation or minimizing pure soybean oil lipid emulsions (typically to $1 \\mathrm{~g} / \\mat"
    },
    {
      "type": "text",
      "section": "Lipid Emulsions and IFALD",
      "line": 878,
      "preview": "- Risk of EFAD and compromised growth"
    },
    {
      "type": "text",
      "section": "Lipid Emulsions and IFALD",
      "line": 880,
      "preview": "--- page 53 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Lipid Emulsions and IFALD - Cont'd",
      "line": 882
    },
    {
      "type": "text",
      "section": "Lipid Emulsions and IFALD - Cont'd",
      "line": 884,
      "preview": "- Composite lipid emulsions (containing soy, medium chain triglycerides, olive oil and fish oil) pro"
    },
    {
      "type": "text",
      "section": "Lipid Emulsions and IFALD - Cont'd",
      "line": 885,
      "preview": "- Helps prevent and possibly treat IFALD in infants and children"
    },
    {
      "type": "text",
      "section": "Lipid Emulsions and IFALD - Cont'd",
      "line": 886,
      "preview": "- Fish oil emulsions provide $\\omega-3$ PUFA, DHA and EHA, $\\alpha$-tocopherol and reduced phytoster"
    },
    {
      "type": "text",
      "section": "Lipid Emulsions and IFALD - Cont'd",
      "line": 887,
      "preview": "- Typically dosed at $1 \\mathrm{~g} / \\mathrm{kg} /$ day; doses of $1.5-2 \\mathrm{~g} / \\mathrm{kg} "
    },
    {
      "type": "text",
      "section": "Lipid Emulsions and IFALD - Cont'd",
      "line": 889,
      "preview": "--- page 54 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Intestinal Failure Nutritional Considerations",
      "line": 891
    },
    {
      "type": "text",
      "section": "Intestinal Failure Nutritional Considerations",
      "line": 893,
      "preview": "- Start enteral feeds as soon as possible and advance as tolerated"
    },
    {
      "type": "text",
      "section": "Intestinal Failure Nutritional Considerations",
      "line": 894,
      "preview": "- Cycle PN when possible"
    },
    {
      "type": "text",
      "section": "Intestinal Failure Nutritional Considerations",
      "line": 895,
      "preview": "- PN is used to meet energy needs and promote normal growth"
    },
    {
      "type": "text",
      "section": "Intestinal Failure Nutritional Considerations",
      "line": 896,
      "preview": "- The patient's response is best and PN should be adjusted to meet nutritional needs and promote nor"
    },
    {
      "type": "text",
      "section": "Intestinal Failure Nutritional Considerations",
      "line": 897,
      "preview": "- Avoid overfeeding"
    },
    {
      "type": "text",
      "section": "Intestinal Failure Nutritional Considerations",
      "line": 898,
      "preview": "- Care within multidisciplinary intestinal rehabilitation teams is beneficial"
    },
    {
      "type": "text",
      "section": "Intestinal Failure Nutritional Considerations",
      "line": 900,
      "preview": "--- page 55 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Case",
      "line": 902
    },
    {
      "type": "text",
      "section": "Case",
      "line": 904,
      "preview": "Lucy is a 5-month-old with biliary atresia and progressive end stage liver disease who is listed for"
    },
    {
      "type": "text",
      "section": "Case",
      "line": 906,
      "preview": "1) What information would you like to assess her nutrition?"
    },
    {
      "type": "text",
      "section": "Case",
      "line": 907,
      "preview": "2) Would you recommend parenteral nutrition and when?"
    },
    {
      "type": "text",
      "section": "Case",
      "line": 908,
      "preview": "3) What factors would influence the energy requirements of this patient?"
    },
    {
      "type": "text",
      "section": "Case",
      "line": 910,
      "preview": "--- page 56 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Case Review",
      "line": 912
    },
    {
      "type": "text",
      "section": "Case Review",
      "line": 914,
      "preview": "Lucy is a 5-month-old with biliary atresia and progressive end stage liver"
    },
    {
      "type": "text",
      "section": "Case Review",
      "line": 915,
      "preview": "disea 1) What information would you like to assess her nutrition?"
    },
    {
      "type": "text",
      "section": "Case Review",
      "line": 916,
      "preview": "$\\checkmark$ Anthropometrics like weight, length, weight for length, head circumference; ideally add"
    },
    {
      "type": "text",
      "section": "Case Review",
      "line": 917,
      "preview": "$\\checkmark$ Feeding history, including feeding tolerance, vomiting, diarrhea"
    },
    {
      "type": "text",
      "section": "Case Review",
      "line": 918,
      "preview": "1) $\\checkmark$ Presence of ascites that can impact feeding tolerance and weight interpretation"
    },
    {
      "type": "text",
      "section": "Case Review",
      "line": 919,
      "preview": "2) $\\checkmark$ CRP at admission"
    },
    {
      "type": "text",
      "section": "Case Review",
      "line": 921,
      "preview": "--- page 57 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Case Review Cont'd",
      "line": 923
    },
    {
      "type": "text",
      "section": "Case Review Cont'd",
      "line": 925,
      "preview": "Lucy is a 5-month-old with biliary atresia and progressive end stage liver disease who is listed for"
    },
    {
      "type": "text",
      "section": "Case Review Cont'd",
      "line": 927,
      "preview": "Should recommence enteral nutrition support ideally within 24 h and plan to advance to meet $60 \\%$ "
    },
    {
      "type": "text",
      "section": "Case Review Cont'd",
      "line": 928,
      "preview": "2) Would you recommend parenteral nutrition and when?"
    },
    {
      "type": "text",
      "section": "Case Review Cont'd",
      "line": 929,
      "preview": "3) What factors would influence the energy requirements of this patient?"
    },
    {
      "type": "text",
      "section": "Case Review Cont'd",
      "line": 931,
      "preview": "--- page 58 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Case Review Cont'd",
      "line": 933
    },
    {
      "type": "text",
      "section": "Case Review Cont'd",
      "line": 935,
      "preview": "Lucy is a 5-month-old with biliary atresia and progressive end stage liver disease who is listed for"
    },
    {
      "type": "text",
      "section": "Case Review Cont'd",
      "line": 936,
      "preview": "fo"
    },
    {
      "type": "text",
      "section": "Case Review Cont'd",
      "line": 937,
      "preview": "3) What factors would influence the energy requirements of this patient?"
    },
    {
      "type": "text",
      "section": "Case Review Cont'd",
      "line": 938,
      "preview": "$\\checkmark$ Energy requirements are generally increased in liver failure"
    },
    {
      "type": "text",
      "section": "Case Review Cont'd",
      "line": 939,
      "preview": "$\\checkmark$ Sepsis can also increase energy requirements"
    },
    {
      "type": "text",
      "section": "Case Review Cont'd",
      "line": 940,
      "preview": "$\\checkmark$ Sedation and mechanical ventilation will both decrease energy needs"
    },
    {
      "type": "text",
      "section": "Case Review Cont'd",
      "line": 941,
      "preview": "$\\checkmark$ NPO and use of PN will also decrease total energy requirements"
    },
    {
      "type": "text",
      "section": "Case Review Cont'd",
      "line": 943,
      "preview": "1) What information would you like to assess her nutrition?"
    },
    {
      "type": "text",
      "section": "Case Review Cont'd",
      "line": 944,
      "preview": "2) Would you recommend parenteral nutrition and when?"
    },
    {
      "type": "text",
      "section": "Case Review Cont'd",
      "line": 945,
      "preview": "3) What factors would influence the energy requirements of this patient?"
    }
  ],
  "images": [
    {
      "sha_name": "a539799643230942.png",
      "original_ref": "img-0.jpeg",
      "page": 3,
      "relative_path": "images/a539799643230942.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/a539799643230942.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "a539799643230942"
    },
    {
      "sha_name": "013681fe3fbd5a0a.png",
      "original_ref": "img-1.jpeg",
      "page": 3,
      "relative_path": "images/013681fe3fbd5a0a.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/013681fe3fbd5a0a.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "013681fe3fbd5a0a"
    },
    {
      "sha_name": "8324f0d123479d4e.png",
      "original_ref": "img-2.jpeg",
      "page": 3,
      "relative_path": "images/8324f0d123479d4e.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/8324f0d123479d4e.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "8324f0d123479d4e"
    },
    {
      "sha_name": "0f19ada61a1b6016.png",
      "original_ref": "img-3.jpeg",
      "page": 4,
      "relative_path": "images/0f19ada61a1b6016.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/0f19ada61a1b6016.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "0f19ada61a1b6016"
    },
    {
      "sha_name": "b655ac13d660bc34.png",
      "original_ref": "img-4.jpeg",
      "page": 4,
      "relative_path": "images/b655ac13d660bc34.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/b655ac13d660bc34.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "b655ac13d660bc34"
    },
    {
      "sha_name": "043b2541a4580ede.png",
      "original_ref": "img-5.jpeg",
      "page": 4,
      "relative_path": "images/043b2541a4580ede.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/043b2541a4580ede.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "043b2541a4580ede"
    },
    {
      "sha_name": "1800be7bdf53c13f.png",
      "original_ref": "img-6.jpeg",
      "page": 5,
      "relative_path": "images/1800be7bdf53c13f.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/1800be7bdf53c13f.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "1800be7bdf53c13f"
    },
    {
      "sha_name": "2826f026e7c8a01c.png",
      "original_ref": "img-7.jpeg",
      "page": 5,
      "relative_path": "images/2826f026e7c8a01c.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/2826f026e7c8a01c.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "2826f026e7c8a01c"
    },
    {
      "sha_name": "ac8a03468b7f0976.png",
      "original_ref": "img-8.jpeg",
      "page": 8,
      "relative_path": "images/ac8a03468b7f0976.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/ac8a03468b7f0976.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "ac8a03468b7f0976"
    },
    {
      "sha_name": "fed14a0d18f5548f.png",
      "original_ref": "img-9.jpeg",
      "page": 16,
      "relative_path": "images/fed14a0d18f5548f.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/fed14a0d18f5548f.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "fed14a0d18f5548f"
    },
    {
      "sha_name": "88f8236e627e47f6.png",
      "original_ref": "img-10.jpeg",
      "page": 16,
      "relative_path": "images/88f8236e627e47f6.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/88f8236e627e47f6.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "88f8236e627e47f6"
    },
    {
      "sha_name": "d062e973d383167c.png",
      "original_ref": "img-11.jpeg",
      "page": 21,
      "relative_path": "images/d062e973d383167c.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/d062e973d383167c.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "d062e973d383167c"
    },
    {
      "sha_name": "334459a1fcc1637a.png",
      "original_ref": "img-12.jpeg",
      "page": 21,
      "relative_path": "images/334459a1fcc1637a.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/334459a1fcc1637a.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "334459a1fcc1637a"
    },
    {
      "sha_name": "42365217c90fcc33.png",
      "original_ref": "img-13.jpeg",
      "page": 21,
      "relative_path": "images/42365217c90fcc33.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/42365217c90fcc33.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "42365217c90fcc33"
    },
    {
      "sha_name": "3bd31495da6374cd.png",
      "original_ref": "img-14.jpeg",
      "page": 23,
      "relative_path": "images/3bd31495da6374cd.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/3bd31495da6374cd.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "3bd31495da6374cd"
    },
    {
      "sha_name": "5212fcce0f1d5c83.png",
      "original_ref": "img-15.jpeg",
      "page": 23,
      "relative_path": "images/5212fcce0f1d5c83.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/5212fcce0f1d5c83.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "5212fcce0f1d5c83"
    },
    {
      "sha_name": "7dd0884bfa68c9e1.png",
      "original_ref": "img-16.jpeg",
      "page": 23,
      "relative_path": "images/7dd0884bfa68c9e1.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/7dd0884bfa68c9e1.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "7dd0884bfa68c9e1"
    },
    {
      "sha_name": "d41f0f0ac4faf52a.png",
      "original_ref": "img-17.jpeg",
      "page": 23,
      "relative_path": "images/d41f0f0ac4faf52a.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/d41f0f0ac4faf52a.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "d41f0f0ac4faf52a"
    },
    {
      "sha_name": "4c7f034388bc031e.png",
      "original_ref": "img-18.jpeg",
      "page": 26,
      "relative_path": "images/4c7f034388bc031e.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/4c7f034388bc031e.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "4c7f034388bc031e"
    },
    {
      "sha_name": "ce657b2ee5d99ffa.png",
      "original_ref": "img-19.jpeg",
      "page": 26,
      "relative_path": "images/ce657b2ee5d99ffa.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/ce657b2ee5d99ffa.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "ce657b2ee5d99ffa"
    },
    {
      "sha_name": "6609086828645fe4.png",
      "original_ref": "img-20.jpeg",
      "page": 50,
      "relative_path": "images/6609086828645fe4.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/8PN PN for Specialized Patient/images/6609086828645fe4.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "6609086828645fe4"
    }
  ],
  "extraction": {
    "ocr_model": "mistral-ocr-latest",
    "request_id": "local-1754696175",
    "ts": "2025-08-08T23:36:15.116365+00:00"
  }
}